Literature DB >> 14643269

Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study.

Kwo-Chang Ueng1, Tsung-Po Tsai, Wen-Chung Yu, Chin-Feng Tsai, Ming-Cheng Lin, Kuei-Chuan Chan, Chung-Yin Chen, Der-Jinn Wu, Chung-Sheng Lin, Shih-Ann Chen.   

Abstract

AIMS: This study aimed to assess whether enalapril could improve cardioversion outcome and facilitate sinus rhythm maintenance after conversion of chronic atrial fibrillation (AF). METHODS AND
RESULTS: Patients with chronic AF for more than 3 months were assigned to receive either amiodarone (200mg orally 3 times a day; group I: n=75) or the same dosage of amiodarone plus enalapril (10mg twice a day; group II: n=70) 4 weeks before scheduled external cardioversion. The end-point was the time to first recurrence of AF. In 125 patients (86.2%), AF was converted to sinus rhythm. Group II had a trend to a trend to a lower rate of immediate recurrence of AF than group I did (4.3% vs 14.7%, P=0.067). Kaplan-Meier analysis demonstrated a higher probability of group II remaining in sinus rhythm at 4 weeks (84.3% vs 61.3%, P=0.002) and at the median follow-up period of 270 days (74.3% vs 57.3%, P=0.021) than in group II.
CONCLUSIONS: The addition of enalapril to amiodarone decreased the rate of immediate and subacute arrhythmia recurrences and facilitated subsequent long-term maintenance of sinus rhythm after cardioversion of persistent AF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643269     DOI: 10.1016/j.ehj.2003.08.014

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  39 in total

1.  Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?

Authors:  Stanley Nattel
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

Review 2.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

3.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

4.  [Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference].

Authors:  P Kirchhof; A Goette; G Hindricks; S Hohnloser; K-H Kuck; T Meinertz; U Ravens; G Steinbeck; G Breithardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

5.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 6.  Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?

Authors:  Annamaria Mascolo; Konrad Urbanek; Antonella De Angelis; Maurizio Sessa; Cristina Scavone; Liberato Berrino; Giuseppe Massimo Claudio Rosano; Annalisa Capuano; Francesco Rossi
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 7.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

Review 8.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.

Authors:  Giuseppina Novo; Daniela Guttilla; Giovanni Fazio; Debbie Cooper; Salvatore Novo
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

10.  Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.

Authors:  Rafik R Anis
Journal:  Exp Clin Cardiol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.